RC

Rakesh Chinnala

Active Director Director DIN 06794818
DIN 06794818 First appointment Feb 2014 Primary industry Pharma
Unlock full profile Investments · shareholding · contact details
Current companies 6 active board seats
Past companies 1 historical roles
Total affiliations 7 Since Feb 2014
Shareholding value •••• Premium profile

About Rakesh Chinnala

Data last updated:

Rakesh Chinnala is a Director at Glukem Biocare Private Limited (since 2014), Director at Tryko Projects Private Limited (since 2021) and Director at Glukem Pharma Private Limited (since 2025), and holds 3 more current directorships. The companies operate in Pharma, Real Estate and Construction and Aviation. The 2 current companies with reported revenue have a combined latest revenue of ₹114 Cr; the largest is Glukem Biocare Private Limited at ₹108 Cr (FY 2025). Earlier, Rakesh Chinnala was a Director at Gencell Pharmaceuticals Private Limited (from 2014).

DIN 06794818
Primary Designation Director
Industry Pharma
First Appointment 04 Feb 2014
Oldest Company Age 22 yrs
Largest company Glukem Biocare Private Limited · ₹108 Cr (FY 2025)
Combined revenue ₹114 Cr across 2 companies

Current companies

CompanyDesignationAppointmentFoundedRevenueStatus
Glukem Biocare Private Limited U24232TG2014PTC096067
Director20 Oct 20142014₹108 Cr (FY 2025)Active
Tryko Projects Private Limited U45402TG2021PTC154647
Director04 Sep 20212021₹5.36 Cr (FY 2024)Active
Glukem Pharma Private Limited U21001TS2025PTC197863
Director29 Apr 20252025Active
Partner01 Jul 20242022Active
Director01 Aug 20152009Active
Voyage Pharma Private Limited U24100TG2014PTC092751
Director04 Feb 20142014Active

Previous companies

CompanyDesignationAppointmentFoundedRevenueStatus
Director06 Dec 20142004₹85.2 Lakh (FY 2016)Strike Off

Explore Director's current and past company associations Uncover their professional journey today!

Directorship timeline

Open interactive timeline →
Voyage Pharma Private Limited
Glukem Biocare Private Limited
Glukem Pharmaceuticals Private Limited
Gencell Pharmaceuticals Private Limited
Premium access

Shareholding and investment profile for Rakesh Chinnala

Company-level share counts, filed values, and quarterly changes require authenticated premium access.

  • Company-level holdings
  • Filed share counts
  • Reported values
  • Quarterly changes
Unlock shareholding

Verified entity values are shown only after access is granted.

Frequently Asked Questions about Rakesh Chinnala

Rakesh Chinnala currently holds 6 directorships: Glukem Biocare Private Limited (Director, since 20 Oct 2014, revenue ₹108 Cr (FY 2025)); Tryko Projects Private Limited (Director, since 04 Sep 2021, revenue ₹5.36 Cr (FY 2024)); Glukem Pharma Private Limited (Director, since 29 Apr 2025); Alasus Technologies Llp (Partner, since 01 Jul 2024); Glukem Pharmaceuticals Private Limited (Director, since 01 Aug 2015); and 1 more.

Rakesh Chinnala was first appointed on 04 Feb 2014 as Director at Voyage Pharma Private Limited. The most recent appointment on record is 29 Apr 2025 at Glukem Pharma Private Limited.

The 2 current companies of Rakesh Chinnala that report revenue have a combined latest revenue of ₹114 Cr: Glukem Biocare Private Limited ₹108 Cr (FY 2025); Tryko Projects Private Limited ₹5.36 Cr (FY 2024).

Rakesh Chinnala held 1 earlier board appointment: Gencell Pharmaceuticals Private Limited (Director, from 06 Dec 2014).

The current boards of Rakesh Chinnala's companies include Hazra Susanta Kumar (Glukem Biocare Private Limited), Omkar Reddy Bommu (Glukem Biocare Private Limited), Ramanaiah Madupaduga (Glukem Biocare Private Limited), Rami Reddy Kolli (Glukem Biocare Private Limited), Varun Vihar Madupaduga (Glukem Biocare Private Limited), Raghavendra Kumar Kandula (Tryko Projects Private Limited), among others.

Explore millions of companies — effortlessly

Access structured, verified intelligence on 7M+ companies across industries, sectors, and global markets. From early-stage startups to large enterprises, discover ownership, leadership, funding, financials, acquisitions, and market signals — all in one powerful platform.

Free account with essential features Instant access to company reports Enterprise solutions available